Calcitonin and amylin receptor peptide interaction mechanisms: Insights into peptide-binding modes and allosteric modulation of the calcitonin receptor by receptor activity-modifying proteins

Journal of Biological Chemistry

Volumn 291, Issue 16, 2016, Pages 8686-8700

  Lee, Sang Min ^a   Hay, Debbie L ^b,c   Pioszak, Augen A ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; BINDING ENERGY; BINS; CELL SIGNALING; COMPUTERIZED TOMOGRAPHY; PEPTIDES;

ALANINE-SCANNING MUTAGENESIS; ALLOSTERIC MODULATION; CALCITONIN GENE-RELATED PEPTIDES; CALCITONIN RECEPTORS; EXTRACELLULAR DOMAINS; INTERACTION MECHANISMS; RECEPTOR ACTIVITY-MODIFYING PROTEINS; SALMON CALCITONIN;

PROTEINS;

ADRENOMEDULLIN RECEPTOR; ALANINE; AMYLIN RECEPTOR; CALCITONIN RECEPTOR; SALCATONIN; TYROSINE; PEPTIDE; RAMP1 PROTEIN, HUMAN; RAMP2 PROTEIN, HUMAN; RECEPTOR ACTIVITY MODIFYING PROTEIN 1; RECEPTOR ACTIVITY MODIFYING PROTEIN 2;

ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; HUMAN; HUMAN CELL; MUTAGENESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN MOTIF; RECEPTOR BINDING; ALLOSTERISM; CHEMISTRY; GENETICS; HEK293 CELL LINE; METABOLISM; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE;

ALLOSTERIC REGULATION; AMINO ACID MOTIFS; HEK293 CELLS; HUMANS; PEPTIDES; PROTEIN STRUCTURE, TERTIARY; RECEPTOR ACTIVITY-MODIFYING PROTEIN 1; RECEPTOR ACTIVITY-MODIFYING PROTEIN 2; RECEPTORS, CALCITONIN; RECEPTORS, ISLET AMYLOID POLYPEPTIDE;

EID: 84964961766     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M115.713628     Document Type: Article

References (55)

1. McLatchie, L. M., Fraser, N. J., Main, M. J., Wise, A., Brown, J., Thompson, N., Solari, R., Lee, M. G., and Foord, S. M. (1998) RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 393, 333-339
2. Hay, D. L., and Pioszak, A. A. (2016) Receptor activity-modifying proteins (RAMPs): new insights and roles. Annu. Rev. Pharmacol. Toxicol. 56, 469-487
3. Hay, D. L., Poyner, D. R., and Sexton, P. M. (2006) GPCR modulation by RAMPs. Pharmacol. Ther. 109, 173-197
4. Poyner, D. R., Sexton, P. M., Marshall, I., Smith, D. M., Quirion, R., Born, W., Muff, R., Fischer, J. A., and Foord, S. M. (2002) International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors. Pharmacol. Rev. 54, 233-246
5. Hong, Y., Hay, D. L., Quirion, R., and Poyner, D. R. (2012) The pharmacology of adrenomedullin 2/intermedin. Br. J. Pharmacol. 166, 110-120
6. Armour, S. L., Foord, S., Kenakin, T., and Chen, W. J. (1999) Pharmacological characterization of receptor-activity-modifying proteins (RAMPs) and the human calcitonin receptor. J. Pharmacol. Toxicol. Methods 42, 217-224
7. Christopoulos, G., Perry, K. J., Morfis, M., Tilakaratne, N., Gao, Y., Fraser, N. J., Main, M. J., Foord, S. M., and Sexton, P. M. (1999) Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product. Mol. Pharmacol. 56, 235-242
8. Muff, R., Bühlmann, N., Fischer, J. A., and Born, W. (1999) An amylin receptor is revealed following co-transfection of a calcitonin receptor with receptor activity modifying proteins-1 or -3. Endocrinology 140, 2924-2927
9. Tilakaratne, N., Christopoulos, G., Zumpe, E. T., Foord, S. M., and Sexton, P. M. (2000) Amylin receptor phenotypes derived from human calcitonin receptor/RAMP coexpression exhibit pharmacological differences dependent on receptor isoform and host cell environment. J. Pharmacol. Exp. Ther. 294, 61-72
10. Hay, D. L., Christopoulos, G., Christopoulos, A., Poyner, D. R., and Sexton, P. M. (2005) Pharmacological discrimination of calcitonin receptor: receptor activity-modifying protein complexes. Mol. Pharmacol. 67, 1655-1665
11. Udawela, M., Christopoulos, G., Tilakaratne, N., Christopoulos, A., Albiston, A., and Sexton, P. M. (2006) Distinct receptor activity-modifying protein domains differentially modulate interaction with calcitonin receptors. Mol. Pharmacol. 69, 1984-1989
12. Brain, S. D., and Grant, A. D. (2004) Vascular actions of calcitonin generelated peptide and adrenomedullin. Physiol. Rev. 84, 903-934
13. Bell, I. M. (2014) Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine. J. Med. Chem. 57, 7838-7858
14. Wong, H. K., Cheung, T. T., and Cheung, B. M. (2012) Adrenomedullin and cardiovascular diseases. JRSM Cardiovasc. Dis. 1, 14
15. Hilton, J. M., Dowton, M., Houssami, S., and Sexton, P. M. (2000) Identification of key components in the irreversibility of salmon calcitonin binding to calcitonin receptors. J. Endocrinol. 166, 213-226
16. Chesnut, C. H., 3rd, Azria, M., Silverman, S., Engelhardt, M., Olson, M., and Mindeholm, L. (2008) Salmon calcitonin: a review of current and future therapeutic indications. Osteoporos. Int. 19, 479-491
17. Hay, D. L., Chen, S., Lutz, T. A., Parkes, D. G., and Roth, J. D. (2015) Amylin: pharmacology, physiology, and clinical potential. Pharmacol. Rev. 67, 564-600
18. Sadry, S. A., and Drucker, D. J. (2013) Emerging combinatorial hormone therapies for the treatment of obesity and T2DM. Nat. Rev. Endocrinol. 9, 425-433
19. Venkatanarayan, A., Raulji, P., Norton, W., Chakravarti, D., Coarfa, C., Su, X., Sandur, S. K., Ramirez, M. S., Lee, J., Kingsley, C. V., Sananikone, E. F., Rajapakshe, K., Naff, K., Parker-Thornburg, J., Bankson, J. A., et al. (2015) IAPP-driven metabolic reprogramming induces regression of p53-deficient tumours in vivo. Nature 517, 626-630
20. Andreassen, K. V., Feigh, M., Hjuler, S. T., Gydesen, S., Henriksen, J. E., Beck-Nielsen, H., Christiansen, C., Karsdal, M. A., and Henriksen, K. (2014)Anovel oral dual amylin and calcitonin receptor agonist (KBP-042) exerts antiobesity and antidiabetic effects in rats. Am. J. Physiol. Endocrinol. Metab. 307, E24-E33
21. Mack, C. M., Soares, C. J., Wilson, J. K., Athanacio, J. R., Turek, V. F., Trevaskis, J. L., Roth, J. D., Smith, P. A., Gedulin, B., Jodka, C. M., Roland, B. L., Adams, S. H., Lwin, A., Herich, J., Laugero, K. D., et al. (2010) Davalintide (AC2307), a novel amylin-mimetic peptide: enhanced pharmacological properties over native amylin to reduce food intake and body weight. Int. J. Obes. 34, 385-395
22. Hoare, S. R. (2005) Mechanisms of peptide and nonpeptide ligand binding to Class B G-protein-coupled receptors. Drug Discov. Today 10, 417-427
23. Barwell, J., Gingell, J. J., Watkins, H. A., Archbold, J. K., Poyner, D. R., and Hay, D. L. (2012) Calcitonin and calcitonin receptor-like receptors: common themes with family B GPCRs? Br. J. Pharmacol. 166, 51-65
24. Booe, J. M., Walker, C. S., Barwell, J., Kuteyi, G., Simms, J., Jamaluddin, M. A., Warner, M. L., Bill, R. M., Harris, P. W., Brimble, M. A., Poyner, D. R., Hay, D. L., and Pioszak, A. A. (2015) Structural basis for receptor activity-modifying protein-dependent selective peptide recognition by a G protein-coupled receptor. Mol. Cell 58, 1040-1052
25. Hill, H. E., and Pioszak, A. A. (2013) Bacterial expression and purification of a heterodimeric adrenomedullin receptor extracellular domain complex using DsbC-assisted disulfide shuffling. Protein Exp. Purif. 88, 107-113
26. Koth, C. M., Abdul-Manan, N., Lepre, C. A., Connolly, P. J., Yoo, S., Mohanty, A. K., Lippke, J. A., Zwahlen, J., Coll, J. T., Doran, J. D., Garcia-Guzman, M., and Moore, J. M. (2010) Refolding and characterization of a soluble ectodomain complex of the calcitonin gene-related peptide receptor. Biochemistry 49, 1862-1872
27. Kusano, S., Kukimoto-Niino, M., Hino, N., Ohsawa, N., Okuda, K., Sakamoto, K., Shirouzu, M., Shindo, T., and Yokoyama, S. (2012) Structural basis for extracellular interactions between calcitonin receptor-like receptor and receptor activity-modifying protein 2 for adrenomedullin-specific binding. Protein Sci. 21, 199-210
28. Watkins, H. A., Au, M., Bobby, R., Archbold, J. K., Abdul-Manan, N., Moore, J. M., Middleditch, M. J., Williams, G. M., Brimble, M. A., Dingley, A. J., and Hay, D. L. (2013) Identification of key residues involved in adrenomedullin binding to the AM1 receptor. Br. J. Pharmacol. 169, 143-155
29. Moad, H. E., and Pioszak, A. A. (2013) Selective CGRP and adrenomedullin peptide binding by tethered RAMP-calcitonin receptor-like receptor extracellular domain fusion proteins. Protein Sci. 22, 1775-1785
30. Pioszak, A. A., Parker, N. R., Suino-Powell, K., and Xu, H. E. (2008) Molecular recognition of corticotropin-releasing factor by its G-protein-coupled receptor CRFR1. J. Biol. Chem. 283, 32900-32912
31. Pioszak, A. A., and Xu, H. E. (2008) Molecular recognition of parathyroid hormone by its G protein-coupled receptor. Proc. Natl. Acad. Sci. U.S.A. 105, 5034-5039
32. Pal, K., Swaminathan, K., Xu, H. E., and Pioszak, A. A. (2010) Structural basis for hormone recognition by the human CRFR2+ G protein-coupled receptor. J. Biol. Chem. 285, 40351-40361
33. Lee, S. M., Booe, J. M., and Pioszak, A. A. (2015) Structural insights into ligand recognition and selectivity for classes A, B, and C GPCRs. Eur. J. Pharmacol. 763, 196-205
34. Pioszak, A. A., Parker, N. R., Gardella, T. J., and Xu, H. E. (2009) Structural basis for parathyroid hormone-related protein binding to the parathyroid hormone receptor and design of conformation-selective peptides. J. Biol. Chem. 284, 28382-28391
35. Zumpe, E. T., Tilakaratne, N., Fraser, N. J., Christopoulos, G., Foord, S. M., and Sexton, P. M. (2000) Multiple ramp domains are required for generation of amylin receptor phenotype from the calcitonin receptor gene product. Biochem. Biophys. Res. Commun. 267, 368-372
36. Aricescu, A. R., Lu, W., and Jones, E. Y. (2006) A time- and cost-efficient system for high-level protein production in mammalian cells. Acta Crystallogr. D Biol. Crystallogr. 62, 1243-1250
37. Thompson, J. D., Gibson, T. J., Plewniak, F., Jeanmougin, F., and Higgins, D. G. (1997) The CLUSTAL-X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res. 25, 4876-4882
38. Warner, M. L., Bell, T., and Pioszak, A. A. (2015) Engineering high-potency R-spondin adult stem cell growth factors. Mol. Pharmacol. 87, 410-420
39. Guex, N., Peitsch, M. C., and Schwede, T. (2009) Automated comparative protein structure modeling with SWISS-MODEL and Swiss-PdbViewer: a historical perspective. Electrophoresis 30, S162-S173
40. Ho, H. H., Gilbert, M. T., Nussenzveig, D. R., and Gershengorn, M. C. (1999) Glycosylation is important for binding to human calcitonin receptors. Biochemistry 38, 1866-1872
41. Wookey, P. J., Tikellis, C., Du, H. C., Qin, H. F., Sexton, P. M., and Cooper, M. E. (1996) Amylin binding in rat renal cortex, stimulation of adenylyl cyclase, and activation of plasma renin. Am. J. Physiol. 270, F289-F294
42. Young, A. A., Gedulin, B., Gaeta, L. S., Prickett, K. S., Beaumont, K., Larson, E., and Rink, T. J. (1994) Selective amylin antagonist suppresses rise in plasma lactate after intravenous glucose in the rat. Evidence for a metabolic role of endogenous amylin. FEBS Lett. 343, 237-241
43. Younk, L. M., Mikeladze, M., and Davis, S. N. (2011) Pramlintide and the treatment of diabetes: a review of the data since its introduction. Expert Opin. Pharmacother. 12, 1439-1451
44. Rist, B., Entzeroth, M., and Beck-Sickinger, A. G. (1998) From micromolar to nanomolar affinity: a systematic approach to identify the binding site of CGRP at the human calcitonin gene-related peptide 1 receptor. J. Med. Chem. 41, 117-123
45. Parthier, C., Kleinschmidt, M., Neumann, P., Rudolph, R., Manhart, S., Schlenzig, D., Fanghanel, J., Rahfeld, J. U., Demuth, H. U., and Stubbs, M. T. (2007) Crystal structure of the incretin-bound extracellular domain of a G protein-coupled receptor. Proc. Natl. Acad. Sci. U.S.A. 104, 13942-13947
46. Runge, S., Thøgersen, H., Madsen, K., Lau, J., and Rudolph, R. (2008) Crystal structure of the ligand-bound glucagon-like peptide-1 receptor extracellular domain. J. Biol. Chem. 283, 11340-11347
47. Morfis, M., Tilakaratne, N., Furness, S. G., Christopoulos, G., Werry, T. D., Christopoulos, A., and Sexton, P. M. (2008) Receptor activity-modifying proteins differentially modulate the G protein-coupling efficiency of amylin receptors. Endocrinology 149, 5423-5431
48. Purdue, B. W., Tilakaratne, N., and Sexton, P. M. (2002) Molecular pharmacology of the calcitonin receptor. Receptors Channels 8, 243-255
49. Wang, Y., Dou, H., Cao, C., Zhang, N., Ma, J., Mao, J., and Wu, H. (2003) Solution structure and biological activity of recombinant salmon calcitonin S-sulfonated analog. Biochem. Biophys. Res. Commun. 306, 582-589
50. Andreotti, G., Méndez, B. L., Amodeo, P., Morelli, M. A., Nakamuta, H., and Motta, A. (2006) Structural determinants of salmon calcitonin bioactivity: the role of the Leu-based amphipathic α-helix. J. Biol. Chem. 281, 24193-24203
51. Patil, S. M., Xu, S., Sheftic, S. R., and Alexandrescu, A. T. (2009) Dynamic α-helix structure of micelle-bound human amylin. J. Biol. Chem. 284, 11982-11991
52. Nanga, R. P., Brender, J. R., Xu, J., Hartman, K., Subramanian, V., and Ramamoorthy, A. (2009) Three-dimensional structure and orientation of rat islet amyloid polypeptide protein in a membrane environment by solution NMR spectroscopy. J. Am. Chem. Soc. 131, 8252-8261
53. Roberts, A. N., Leighton, B., Todd, J. A., Cockburn, D., Schofield, P. N., Sutton, R., Holt, S., Boyd, Y., Day, A. J., and Foot, E. A. (1989) Molecular and functional characterization of amylin, a peptide associated with type 2 diabetes mellitus. Proc. Natl. Acad. Sci. U.S.A. 86, 9662-9666
54. Gingell, J. J., Qi, T., Bailey, R. J., and Hay, D. L. (2010) A key role for tryptophan 84 in receptor activity-modifying protein 1 in the amylin 1 receptor. Peptides 31, 1400-1404
55. Moore, E. L., Gingell, J. J., Kane, S. A., Hay, D. L., and Salvatore, C. A. (2010) Mapping the CGRP receptor ligand binding domain: tryptophan-84 of RAMP1 is critical for agonist and antagonist binding. Biochem. Biophys. Res. Commun. 394, 141-145